Basics Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat. IPO Date: July 31, 1996 Sector: Healthcare Industry: Biotech Market Cap: $859.83M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 2.88% Avg Daily Range (30 D): $0.06 | 3.83% Avg Daily Range (90 D): $0.07 | 3.12% Institutional Daily Volume Avg Daily Volume: 2.69M Avg Daily Volume (30 D): 11.77M Avg Daily Volume (90 D): 12.91M Trade Size Avg Trade Size (Sh.): 342 Avg Trade Size (Sh.) (30 D): 584 Avg Trade Size (Sh.) (90 D): 532 Institutional Trades Total Inst.Trades: 2,549 Avg Inst. Trade: $1.89M Avg Inst. Trade (30 D): $1.55M Avg Inst. Trade (90 D): $2.16M Avg Inst. Trade Volume: .6M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.42M Avg Closing Trade (30 D): $1.65M Avg Closing Trade (90 D): $2.48M Avg Closing Volume: 805.29K         News Apr 29, 2025 @ 2:00 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: N/A Apr 29, 2025 @ 1:00 AM Bragar Eagel & Squire, P.C. Reminds Investors That... Source: N/A Apr 28, 2025 @ 10:50 PM Geron Corporation Investors: Please contact the Po... Source: N/A Apr 27, 2025 @ 8:14 PM ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy ... Source: N/A Apr 24, 2025 @ 5:49 PM ROSEN, A LEADING NATIONAL FIRM, Encourages Geron C... Source: N/A Financials   TTM Q4 2024 FY 2024 Basic EPS $-.27 $-.04 $-.27 Diluted EPS $-.27 $-.04 $-.27 Revenue $ 76.99M $ 47.54M $ 76.99M Gross Profit $ $ $ Net Income / Loss $ -174.57M $ -25.35M $ -174.57M Operating Income / Loss $ -173.73M $ -20.05M $ -173.73M Cost of Revenue $ $ $ Net Cash Flow $ 9.75M $ 18.71M $ 9.75M PE Ratio